Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Incyte Corp (NASDAQ: INCY) closed at $67.38 down -0.71% from its previous closing price of $67.86. In other words, the price has decreased by -$0.71 from its previous closing price. On the day, 1.33 million shares were traded. INCY stock price reached its highest trading level at $68.63 during the session, while it also had its lowest trading level at $67.17.
Ratios:
For a deeper understanding of Incyte Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.41 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 43.09. For the most recent quarter (mrq), Quick Ratio is recorded 2.00 and its Current Ratio is at 2.04. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 21 ’25 when STEVEN STEIN bought 3,706 shares for $67.94 per share.
Flannelly Barry P sold 1,340 shares of INCY for $91,602 on Jul 16 ’25. The EVP & General Manager US now owns 35,149 shares after completing the transaction at $68.36 per share. On Jul 16 ’25, another insider, Iyengar Vijay K, who serves as the EVP, GMAPPS of the company, sold 983 shares for $68.36 each. As a result, the insider received 67,198 and left with 40,540 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INCY now has a Market Capitalization of 13042746368 and an Enterprise Value of 10816573440. As of this moment, Incyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 208.48, and their Forward P/E ratio for the next fiscal year is 9.86. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.13. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.96 while its Price-to-Book (P/B) ratio in mrq is 3.56. Its current Enterprise Value per Revenue stands at 2.451 whereas that against EBITDA is 35.665.
Stock Price History:
The Beta on a monthly basis for INCY is 0.71, which has changed by 0.040957212 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, INCY has reached a high of $83.95, while it has fallen to a 52-week low of $53.56. The 50-Day Moving Average of the stock is 0.85%, while the 200-Day Moving Average is calculated to be -1.14%.
Shares Statistics:
For the past three months, INCY has traded an average of 1.87M shares per day and 1390600 over the past ten days. A total of 193.78M shares are outstanding, with a floating share count of 190.87M. Insiders hold about 1.39% of the company’s shares, while institutions hold 100.44% stake in the company. Shares short for INCY as of 1749772800 were 8185860 with a Short Ratio of 3.90, compared to 1747267200 on 9470382. Therefore, it implies a Short% of Shares Outstanding of 8185860 and a Short% of Float of 5.9899997.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A comprehensive evaluation of Incyte Corp (INCY) is underway, with the input of 15.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $1.54, with high estimates of $1.66 and low estimates of $1.43.
Analysts are recommending an EPS of between $6.32 and $4.84 for the fiscal current year, implying an average EPS of $5.77. EPS for the following year is $6.71, with 19.0 analysts recommending between $8.26 and $4.15.
Revenue Estimates
A total of 19 analysts believe the company’s revenue will be $1.15B this quarter.It ranges from a high estimate of $1.19B to a low estimate of $1.1B. As of the current estimate, Incyte Corp’s year-ago sales were $1.04BFor the next quarter, 19 analysts are estimating revenue of $1.21B. There is a high estimate of $1.27B for the next quarter, whereas the lowest estimate is $1.18B.
A total of 23 analysts have provided revenue estimates for INCY’s current fiscal year. The highest revenue estimate was $4.86B, while the lowest revenue estimate was $4.59B, resulting in an average revenue estimate of $4.71B. In the same quarter a year ago, actual revenue was $4.24BBased on 23 analysts’ estimates, the company’s revenue will be $5.19B in the next fiscal year. The high estimate is $5.51B and the low estimate is $4.83B.
